5-chloropyrazinamide has been researched along with pyrazinamide in 13 studies
| Studies (5-chloropyrazinamide) | Trials (5-chloropyrazinamide) | Recent Studies (post-2010) (5-chloropyrazinamide) | Studies (pyrazinamide) | Trials (pyrazinamide) | Recent Studies (post-2010) (pyrazinamide) |
|---|---|---|---|---|---|
| 14 | 0 | 7 | 3,626 | 320 | 1,113 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arai, M; Jacobs, WR; Vilchèze, C; Welch, JT; Zimhony, O | 1 |
| Chung, WJ; Jacobs, WR; Ngo, SC; Sayahi, H; Welch, JT; Zimhony, O | 1 |
| Baughn, AD; Deng, J; Jacobs, WR; Riestra, A; Vilchèze, C; Welch, JT; Zimhony, O | 1 |
| Doležal, M; Kubíček, V; Kuneš, J; Paterová, P; Servusová, B; Vobicková, J; Zitko, J | 1 |
| Doležal, M; Kubíček, V; Kučera, R; Kuneš, J; Mandíková, J; Paterová, P; Servusová, B; Zitko, J | 1 |
| Bolívar, BE; Welch, JT | 1 |
| Cynamon, MH; Speirs, RJ; Welch, JT | 1 |
| Cox, JS; Jacobs, WR; Vilchèze, C; Welch, JT; Zimhony, O | 1 |
| Barry, CE; Boshoff, HI; Mizrahi, V | 1 |
| Jacobs, WR; Vilchèze, C; Zimhony, O | 1 |
| Ahmad, Z; Almeida, D; Baughn, AS; Grosset, JH; Jacobs, WR; Minkowsk, A; Nuermberger, EL; Peck, KM; Tyagi, S; Welch, JT | 1 |
| Doležal, M; Hrabcová, V; Kubíček, V; Kučera, R; Kuneš, J; Mandíková, J; Paterová, P; Servusová, B; Soukup, O; Zitko, J | 1 |
| Baughn, AD; Dillon, NA; Peterson, ND; Rosen, BC | 1 |
13 other study(ies) available for 5-chloropyrazinamide and pyrazinamide
| Article | Year |
|---|---|
Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.
Topics: Bacterial Proteins; Fatty Acid Synthases; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrazinamide; Structure-Activity Relationship; Tuberculosis | 2007 |
Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.
Topics: Bacterial Proteins; Cell-Free System; Fatty Acid Synthases; Humans; Inhibitory Concentration 50; Kinetics; Mass Spectrometry; Molecular Structure; Mycobacterium tuberculosis; NADP; Oxidation-Reduction; Pyrazinamide; Reproducibility of Results; Substrate Specificity | 2007 |
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Multiple, Bacterial; Genotype; Mutation; Mycobacterium bovis; Mycobacterium smegmatis; Mycobacterium tuberculosis; Pyrazinamide | 2010 |
Synthesis and antimycobacterial evaluation of N-substituted 5-chloropyrazine-2-carboxamides.
Topics: Amides; Anti-Bacterial Agents; Antitubercular Agents; Mycobacterium tuberculosis; Pyrazines; Structure-Activity Relationship | 2013 |
Alkylamino derivatives of pyrazinamide: synthesis and antimycobacterial evaluation.
Topics: Anti-Bacterial Agents; Antifungal Agents; Antitubercular Agents; Crystallography; Drug Evaluation, Preclinical; Hep G2 Cells; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrazinamide | 2014 |
Studies of the Binding of Modest Modulators of the Human Enzyme, Sirtuin 6, by STD NMR.
Topics: Binding Sites; Crystallography, X-Ray; Humans; Kinetics; Magnetic Resonance Imaging; Niacinamide; Protein Binding; Pyrazinamide; Sirtuins; Thermodynamics | 2017 |
In vitro antimycobacterial activity of 5-chloropyrazinamide.
Topics: Antitubercular Agents; Microbial Sensitivity Tests; Mycobacterium bovis; Mycobacterium tuberculosis; Pyrazinamide | 1998 |
Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Enzyme Inhibitors; Fatty Acid Synthases; Humans; Mycobacterium tuberculosis; Prodrugs; Pyrazinamide; Tuberculosis, Pulmonary | 2000 |
Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I.
Topics: Antitubercular Agents; Bacterial Proteins; Fatty Acid Synthases; Fatty Acids; Hydrogen-Ion Concentration; Mycobacterium tuberculosis; Pyrazinamide | 2002 |
Characterization of Mycobacterium smegmatis expressing the Mycobacterium tuberculosis fatty acid synthase I (fas1) gene.
Topics: Bacterial Proteins; Base Sequence; Fatty Acid Synthases; Fatty Acids; Microbial Sensitivity Tests; Molecular Sequence Data; Mycobacterium smegmatis; Mycobacterium tuberculosis; Pyrazinamide | 2004 |
Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis.
Topics: Animals; Antitubercular Agents; Female; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium bovis; Mycobacterium tuberculosis; Pyrazinamide; Tuberculosis | 2012 |
Synthesis, antimycobacterial activity and in vitro cytotoxicity of 5-chloro-N-phenylpyrazine-2-carboxamides.
Topics: Animals; Antifungal Agents; Antitubercular Agents; Cell Line; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; Humans; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Microbial Sensitivity Tests; Mycobacterium; Pyrazinamide | 2013 |
Pantothenate and pantetheine antagonize the antitubercular activity of pyrazinamide.
Topics: Antitubercular Agents; beta-Alanine; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Niacinamide; Pantetheine; Pantothenic Acid; Pyrazinamide | 2014 |